The NICE AC considered that although the definition of anaemia varies in clinical practice, the definition used in the PEGASUS trial [14] (patients with Hb levels < 10.5 g/dL) included most people who would be considered anaemic after having treatment with eculizumab or ravulizumab. The gene discussed is GSTM1; the disease is anemia.